MedPath

Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects

Not Applicable
Completed
Conditions
Dry Eye Syndrome
Registration Number
NCT01744457
Lead Sponsor
Medical University of Vienna
Brief Summary

Dry Eye Syndrome (DES) is a common condition that affects approximately 20% of adults aged 45 and older. Although several clinical tests for the diagnosis and monitoring of DES are available, currently no gold standard for the assessment of DES exists. It has, however, been hypothesized that the assessment of tear film osmolarity may be a new and promising approach of an objective and non-invasive method for diagnosis and monitoring of treatment success.

Recently, a new commercially available instrument (TearLab®, OcuSens Inc, San Diego, USA) for the assessment of tear film osmolarity has been introduced. This instrument allows for the easy and non-invasive determination of tear film osmolarity. Unfortunately, no data about reproducibility are yet available. Consequently, the current study sets out to investigate the short time reproducibility of tear film osmolarity measurements using the TearLab® instrument.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

Patients with dry eye syndrome (DES):

  • Men and Women aged between 45 and 80 years, with DES defined as a pathological Schirmer I test and / or a pathological break-up time test. Schirmer I test and break up time will be tested and analyzed according to the guidelines published in the Report of the International Dry EyeWorkShop (DEWS) 2007
  • normal findings in the ophthalmic examination other than DES

Healthy control group:

  • Men and Women aged between 45 and 80 years,
  • normal findings in the medical history and ophthalmic examination
Exclusion Criteria
  • Abuse of drugs or alcoholic beverages
  • Participation in a clinical trial
  • Symptoms of a clinically relevant illness

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Coefficient of variation of tear film osmolarity after repeated measurementsMeasurement of tear film osmolarity 3 times daily within 30 minutes for 3 consecutive days
Secondary Outcome Measures
NameTimeMethod
Subjective symptoms assessed using the OSDI teston the screening day
Tear break up timeon 3 consecutive study days once a day
Schirmer I teston 3 consecutive study days once a day
OSI (Objective Scattering Index)on 3 consecutive study days once a day

Trial Locations

Locations (1)

Department of Clinical Pharmacology, Medical University of Vienna

🇦🇹

Vienna, Austria

Department of Clinical Pharmacology, Medical University of Vienna
🇦🇹Vienna, Austria

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.